These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 32603665)

  • 41. IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer.
    Xia J; Zhang L; Peng X; Tu J; Li S; He X; Li F; Qiang J; Dong H; Deng Q; Liu C; Xu J; Zhang R; Liu Q; Hu G; Liu C; Jiang YZ; Shao ZM; Chen C; Liu S
    Cancer Res; 2024 Jul; 84(14):2282-2296. PubMed ID: 38657120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6.
    Yin Y; Yao S; Hu Y; Feng Y; Li M; Bian Z; Zhang J; Qin Y; Qi X; Zhou L; Fei B; Zou J; Hua D; Huang Z
    Clin Cancer Res; 2017 Dec; 23(23):7375-7387. PubMed ID: 28928161
    [No Abstract]   [Full Text] [Related]  

  • 43. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
    Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
    Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Scutellaria barbata D.Don and Scleromitrion diffusum (Willd.) R.J.Wang inhibits the progression of triple negative breast cancer though the activation inhibition of NF-κB triggered by CAFs-derived IL6.
    Pan Y; Ma T; Chen D; Wang Y; Peng Y; Lu T; Yin X; Li H; Zhang G; Wang X
    J Ethnopharmacol; 2024 Dec; 335():118656. PubMed ID: 39121924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Chen X; Ma C; Li Y; Liang Y; Chen T; Han D; Luo D; Zhang N; Zhao W; Wang L; Yang Q
    Oncogene; 2024 Jun; 43(23):1742-1756. PubMed ID: 38609499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
    Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
    Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
    J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
    Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 54. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway.
    Lin L; Luo X; Wang L; Xu F; He Y; Wang Q; Yuan C; Xu J; Yan L; Hao H
    Int Immunopharmacol; 2020 Aug; 85():106625. PubMed ID: 32485356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
    Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
    Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.
    Sahni JM; Gayle SS; Webb BM; Weber-Bonk KL; Seachrist DD; Singh S; Sizemore ST; Restrepo NA; Bebek G; Scacheri PC; Varadan V; Summers MK; Keri RA
    Cancer Res; 2017 Oct; 77(19):5395-5408. PubMed ID: 28807940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.